文献速递胸部肿瘤

早期非小细胞肺癌:2018年胸部肿瘤学进展

Early-Stage NSCLC: Advances in Thoracic Oncology 2018.
PubMed 文献 · J Thorac Oncol · 2019-03-07

本文综述2017年中至2018年底早期非小细胞肺癌(NSCLC)的关键进展,包括基于深度测序的循环肿瘤DNA技术检测根治性治疗后的微小残留病、21例患者术前接受两剂纳武利尤单抗的小型先导研究,以及荷兰-比利时肺癌筛查试验(NELSON)的长期等待结果。这些研究与其他综述工作一起,有望加速实现肺癌早期发现、更多患者接受根治性治疗并获得治愈、以及治疗后失败高风险者早期识别的目标。

要点

  • 2017年6月ASCO年会报告了基于深度测序的循环肿瘤DNA技术检测NSCLC根治性放疗或手术后微小残留病的小型研究。
  • 2018年4月AACR年会报告了21例患者术前接受两剂纳武利尤单抗的小型先导研究。
  • 2018年9月第19届世界肺癌大会报告了荷兰-比利时肺癌筛查试验(NELSON)的长期等待结果。

核心结论

  • 这三项开创性研究及其他综述工作有望加速实现肺癌早期发现、更多患者接受根治性治疗并获得治愈、以及治疗后失败高风险者早期识别的目标。

研究设计与样本

  • 本文为综述,概述2017年中至2018年底早期NSCLC的最新研究进展。

主要发现

  • 2017年6月ASCO年会报告了斯坦福大学Max Diehn组的一项小型研究,使用新型「基于深度测序的癌症个体化分析」循环肿瘤DNA技术检测NSCLC根治性放疗或手术后患者的微小残留病。
  • 2018年4月AACR年会上Drew Pardoll报告了一项21例患者术前接受两剂纳武利尤单抗的小型先导研究。
  • 2018年9月第19届世界肺癌大会上Harry J. De Koning报告了荷兰-比利时肺癌筛查试验(NELSON)的长期等待结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

2018 was a banner year for all thoracic oncology, but especially for early-stage NSCLC. Three seminal events occurred in the approximately 18 months from mid-2017 to the end of 2018: in June 2017 at the American Society of Clinical Oncology Annual Meeting a small, relatively unheralded study from Max Diehn's group at Stanford University reported on the use of a novel "cancer personalized profiling by deep sequencing" circulating tumor-DNA technology to identify minimal residual disease in patients after curative-intent radiation or surgery for NSCLC; in April 2018 at the American Association for Cancer Research Annual Meeting, Drew Pardoll presented a small pilot study of 21 patients who had received two doses of preoperative nivolumab; in September 2018, at the 19th World Conference on Lung Cancer, Harry J. De Koning presented the long-awaited results of the Dutch-Belgian Lung Cancer Screening Trial (NELSON). These three seminal studies, along with others which are reviewed in this paper, promise to accelerate our progress towards a world in which lung cancer is identified early, more patients undergo curative-intent treatment that achieves the promised cure, and those at risk for failure after treatment are identified early, when the cancer remains most vulnerable. The day is around the corner when lung cancer is defanged and no longer the worldwide terror it currently is. We herein present an overview of the most recent body of work that moves us inexorably towards that day.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Osarogiagbon RU, Veronesi G, Fang W, et al. Early-Stage NSCLC: Advances in Thoracic Oncology 2018. J Thorac Oncol. 2019. PMID: 30851441. doi:10.1016/j.jtho.2019.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。